Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor.
Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Giving
ATN-161 together with carboplatin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ATN-161 when
given together with carboplatin and to see how well they work in treating patients with
recurrent malignant glioma.
OBJECTIVES:
Primary
- Establish the safety of ATN-161 and carboplatin in patients with recurrent intracranial
malignant glioma.
- Determine the maximum tolerated dose of ATN-161 when administered with carboplatin in
these patients. (phase I)
- Determine the antitumor activity of ATN-161 when administered with carboplatin in these
patients. (phase II)
Secondary
- Describe the effects of this regimen on potential biomarkers of activity, including
functional imaging with brain perfusion scans and circulating endothelial progenitor
cells.
- Obtain preliminary evidence of efficacy of this regimen in these patients. (phase I)
- Characterize the plasma concentrations of this regimen in these patients. (phase I)
OUTLINE: This is an open-label, phase I dose-escalation study of ATN-161 followed by a phase
II study. Patients in the phase II portion of the study are stratified according to tumor
type (glioblastoma multiforme vs anaplastic glioma).
- Phase I: Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and
carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2,
patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10
minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of
disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of ATN-161 until the maximum tolerated dose
(MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients
experience dose-limiting toxicity during the first 6 weeks of treatment.
- Phase II: Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD
determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for
up to 12 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection at baseline and then periodically during phase I course 1
for pharmacokinetic and pharmacodynamic analysis and at baseline and then periodically
during study for biomarker (e.g., circulating endothelial progenitor cells) correlative
studies.
After completion of study treatment, patients are followed for 28 days.
PROJECTED ACCRUAL: A total of 82 patients will be accrued for this study.
;
Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 |